Log in
NASDAQ:AERI

Aerie Pharmaceuticals Stock Forecast, Price & News

$9.91
+0.23 (+2.38 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.36
Now: $9.91
$9.99
50-Day Range
$9.12
MA: $11.43
$12.25
52-Week Range
$9.01
Now: $9.91
$26.26
Volume1.04 million shs
Average Volume866,176 shs
Market Capitalization$460.95 million
P/E RatioN/A
Dividend YieldN/A
Beta0.83
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Read More
Aerie Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300
Employees380

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$69.89 million
Book Value$3.60 per share

Profitability

Net Income$-199,580,000.00
Net Margins-247.36%

Miscellaneous

Market Cap$460.95 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$9.91
+0.23 (+2.38 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

How has Aerie Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AERI stock has decreased by 31.9% and is now trading at $9.91.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aerie Pharmaceuticals?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aerie Pharmaceuticals
.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Aerie Pharmaceuticals
.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its earnings results on Thursday, August, 6th. The company reported ($0.83) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.04. The firm earned $18.03 million during the quarter, compared to analyst estimates of $18.65 million. Aerie Pharmaceuticals had a negative return on equity of 107.42% and a negative net margin of 247.36%.
View Aerie Pharmaceuticals' earnings history
.

What price target have analysts set for AERI?

15 equities research analysts have issued 1-year price targets for Aerie Pharmaceuticals' stock. Their forecasts range from $9.00 to $50.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $27.29 in the next twelve months. This suggests a possible upside of 175.3% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals
.

Who are some of Aerie Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 67, Pay $1.13M)
  • Mr. Thomas A. Mitro, Pres & COO (Age 62, Pay $582.78k)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 59, Pay $582.51k)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 62, Pay $620.37k)
  • Mr. John W. LaRocca Esq., Gen. Counsel & Assistant Sec. (Age 54, Pay $576.3k)

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.83%), Pinnacle Associates Ltd. (1.13%), CWM LLC (0.45%), Envestnet Asset Management Inc. (0.12%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals
.

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including CWM LLC, and Pinnacle Associates Ltd..
View insider buying and selling activity for Aerie Pharmaceuticals
.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Envestnet Asset Management Inc., and Nisa Investment Advisors LLC. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals
.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $9.91.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $460.95 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 380 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.